Based on the Galectin Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for Galectin Therapeutics Inc is USD 11.00 over the next 12 months. Galectin Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Galectin Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Galectin Therapeutics Inc’s stock price was USD 1.04. Galectin Therapeutics Inc’s stock price has changed by -50.71% over the past week, -63.06% over the past month and -41.57% over the last year.
No recent analyst target price found for Galectin Therapeutics Inc
No recent average analyst rating found for Galectin Therapeutics Inc
Company Overview Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Read Less
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, t...Read More
Frequently Asked Questions About Galectin Therapeutics Inc (GALT) Stock
Based on ratings from 1 analysts Galectin Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on GALT's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for GALT is USD 11.00 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 11.
Unfortunately we do not have enough data on GALT's stock to indicate if its overvalued.
The last closing price of GALT's stock was USD 1.04.
The most recent market capitalization for GALT is USD 0.13B.
Based on targets from 1 analysts, the average taret price for GALT is projected at USD 11.00 over the next 12 months.
This means that GALT's stock price may go up by +957.69% over the next 12 months.
We can't find any ETFs which contains Galectin Therapeutics Inc's stock.
As per our most recent records Galectin Therapeutics Inc has 14 Employees.
Galectin Therapeutics Inc's registered address is 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071.
You can get more information about it from Galectin Therapeutics Inc's website at https://galectintherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Galectin Therapeutics Inc (GALT) Stock
Based on ratings from 1 analysts Galectin Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on GALT's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for GALT is USD 11.00 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 11.
Unfortunately we do not have enough data on GALT's stock to indicate if its overvalued.
The last closing price of GALT's stock was USD 1.04.
The most recent market capitalization for GALT is USD 0.13B.
Based on targets from 1 analysts, the average taret price for GALT is projected at USD 11.00 over the next 12 months.
This means that GALT's stock price may go up by +957.69% over the next 12 months.
We can't find any ETFs which contains Galectin Therapeutics Inc's stock.
As per our most recent records Galectin Therapeutics Inc has 14 Employees.
Galectin Therapeutics Inc's registered address is 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071.
You can get more information about it from Galectin Therapeutics Inc's website at https://galectintherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GALT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
